Return to site
Return to site

Gene Therapy Startup Neurophth Announced the Completion of Round C Financing

· Trends

Neurophth, China's first gene therapy company focusing on ophthalmic diseases, announced the completion of nearly 400 million yuan of round C financing.

 

This round of financing will be used for the internationalization of core products, continuously promote and enrich the company's R&D pipeline projects, and improve the production capacity in international standards. With subsidiaries in Wuhan, Suzhou, Shanghai, and San Diego, Neurophth is committed to discovering and developing gene therapy for patients with genetic diseases worldwide.

 

Neurophth's core product NR082 (rAAV2-ND4, NFS-01) is the first ophthalmic gene therapy drug approved for the clinical trial in China. The phase 1/2/3 clinical trial was completed in June this year, and the first patient was enrolled for administration. The 8000 square meters independent production base built in line with the international (NMPA, FDA, EMA) GMP standards has been completed in September this year. Neurophth has a high-yield and stable wall sticking and suspension production process, which can meet the needs of commercial production of products with different characteristics and scales.

 

Subscribe
Previous
Synthetic Biology Startup Readline Completed Equity...
Next
SBS Genetech's Mutant Proteinase K Powder Price Decrease...
 Return to site
Cookie Use
We use cookies to improve browsing experience, security, and data collection. By accepting, you agree to the use of cookies for advertising and analytics. You can change your cookie settings at any time. Learn More
Accept all
Settings
Decline All
Cookie Settings
Necessary Cookies
These cookies enable core functionality such as security, network management, and accessibility. These cookies can’t be switched off.
Analytics Cookies
These cookies help us better understand how visitors interact with our website and help us discover errors.
Preferences Cookies
These cookies allow the website to remember choices you've made to provide enhanced functionality and personalization.
Save